Please assess the completion status of the following clinical trial:

Trial Title: Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Free, informed, express and written.~* Diagnosis of native kidney primary IgA glomerulonephritis biopsy-proven~* First kidney transplantation (one kidney)~Exclusion Criteria:~* Panel Reactive Antibody (PRA PRA global or class I or class II PRA) over 50% on a serum before transplantation~* Multi-organ graft~* Transplants using donor limits or sub-optimal: donor age ≥ 70 years, donors in the study BIGRAS or taken heart beating donors (tested on computer infusion) or other restriction factors~* IgA glomerulonephritis secondary to HSP (Henoch-Schonlein purpura) or Systemic Lupus Erythematosus (SLE) or alcoholic cirrhosis~* History of cancer older than 5 years or with advanced cancer, but except for non-recurrent skin cancers~* Infectious diseases scalable: tuberculosis, HIV, Hepatitis B virus or Hepatitis C virus infection with viral replication and / or chronic hepatitis~* Allergy to rabbit proteins~* Severe thrombocytopenia (\<50,000 platelets/ul)~* Bacterial infection, viral and fungal uncontrolled therapeutically~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ATG-F (Type: EXPERIMENTAL): The ATG-Fresenius® is administered by slow infusion over four hours after antihistamine (2 bulbs Polaramine® IV) and intravenous methylprednisolone (minimum 30mg); it is started on day 0 prior to surgery at doses of 4 mg / kg, and then continued to day 1, day 2 to 4mg / kg, then day 3, day 4 at the dose of 3 mg / kg
- Simulect (Type: ACTIVE_COMPARATOR): The anti CD25 (basiliximab, Simulect®) is administered intravenously before surgery of renal transplantation (Day 0 and Day + 4 (1 ampoule of 20 mg x 2 times).

Based on this trial design, predict the completion outcome and termination type (if applicable).